help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on September 27, 2007, doi:10.1164/rccm.200705-655OC

Am. J. Respir. Crit. Care Med., Volume 177, Number 1, January 2008, 91-98

A more recent version of this article appeared on January 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200705-655OCv1
177/1/91    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strange, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strange, C.

Submitted on May 2, 2007
Accepted on September 27, 2007

Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease

Charlie Strange1*, Marcy B Bolster2, Michael D Roth3, Richard M Silver2, Arthur Theodore4, Jonathan Goldin5, Philip Clements6, Joanie Chung7, Robert M Elashoff7, Robert Suh5, Edwin A Smith2, Daniel E Furst6, Donald P Tashkin3, and the Scleroderma Lung Study Research Group

1 Department of Medicine, Medical University of South Carolina, Division of Pulmonary and Critical Care Medicine, Charleston, SC, USA, 2 Department of Medicine, Medical University of South Carolina, Division of Rheumatology and Immunology, Charleston, SC, USA, 3 Department of Medicine, David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine, Los Angeles, CA, USA, 4 Department of Medicine, Boston University School of Medicine, Division of Pulmnonary, Allergy and Critical Care Medicine, Boston, MA, USA, 5 Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 6 Department of Medicine, David Geffen School of Medicine at UCLA, Division of Rheumatology and Arthritis, Los Angeles, CA, USA, 7 Department of Biostatistics and Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

* To whom correspondence should be addressed. E-mail: strangec{at}musc.edu.

Rationale: The presence of inflammatory cells on bronchoalveolar lavage is often used to predict disease activity and the need for therapy in systemic sclerosis associated interstitial lung disease. Objectives: To evaluate whether lavage cellularity identifies distinct subsets of disease and/or predicts cyclophosphamide responsiveness. Methods: Patients underwent baseline lavage and/or high resolution computerized tomography as part of a randomized placebo-controlled trial of cyclophosphamide versus placebo (Scleroderma Lung Study) to determine the effect of therapy on forced vital capacity. Patients with ≥ 3% polymorphonuclear and/or ≥ 2 % eosinophilic leukocytes on lavage and/or ground-glass opacification on computed tomography were eligible for enrollment. Measurements and Main Results: Lavage was performed in 201 individuals, including 141 of the 158 randomized patients. Abnormal cellularity was present in 101 of these cases (71.6%) and defined a population with a higher % of men (p= 0.04), more severe lung function including a worse forced vital capacity (p=0.003), total lung capacity (p=0.005), and diffusing capacity of the lung for carbon monoxide (p=0.004), more extensive ground glass opacity (p=0.005) and more extensive fibrosis in the right middle lobe (p=0.005). Despite these relationships, the presence or absence of an abnormal cell differential was not an independent predictor of disease progression or response to cyclophosphamide at one year (p=NS).
Key words: systemic sclerosis, chest computed tomography, Scleroderma Lung Study, BAL, SSc




This article has been cited by other articles:


Home page
 ChestHome page
J. Goldin, R. Elashoff, H. J. Kim, X. Yan, D. Lynch, D. Strollo, M. D. Roth, P. Clements, D. E. Furst, D. Khanna, et al.
Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo: Findings From the Scleroderma Lung Study
Chest, November 1, 2009; 136(5): 1333 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. U. Wells, V. Steen, and G. Valentini
Pulmonary complications: one of the most challenging complications of systemic sclerosis
Rheumatology, June 1, 2009; 48(suppl_3): iii40 - iii44.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K. M. Antoniou, G. Margaritopoulos, F. Economidou, and N. M. Siafakas
Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement
Eur. Respir. J., April 1, 2009; 33(4): 882 - 896.
[Abstract] [Full Text] [PDF]

Home page
 The Journal of RheumatologyHome page
F. N. HANT, A. LUDWICKA-BRADLEY, H.-J. WANG, N. LI, R. ELASHOFF, D. P. TASHKIN, and R. M. SILVER
Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma
J Rheumatol, April 1, 2009; 36(4): 773 - 780.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. Behr and V. J. Thannickal
Update in Diffuse Parenchymal Lung Disease 2008
Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 439 - 444.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. M. Silver and A. U. Wells
Histopathology and bronchoalveolar lavage
Rheumatology, October 1, 2008; 47(suppl_5): v62 - v64.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. G. Goldin, D. A. Lynch, D. C. Strollo, R. D. Suh, D. E. Schraufnagel, P. J. Clements, R. M. Elashoff, D. E. Furst, S. Vasunilashorn, M. F. McNitt-Gray, et al.
High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease
Chest, August 1, 2008; 134(2): 358 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. Strange and J. R. Seibold
Scleroderma Lung Disease: "If You Don't Know Where You Are Going, Any Road Will Take You There"
Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1178 - 1179.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. P. Baughman and G. Raghu
Bronchoalveolar Cellular Analysis in Scleroderma Lung Disease: Does Sutton's Law Hold?
Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 2 - 3.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society